|
|
|
|
Fibrogen Inc (NASDAQ: FGEN) |
|
|
|
| |
Fibrogen Inc 's Working Capital Ratio
FGEN's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth
In the wake of the increase in Current Liabilities in the third quarter 2024, Working Capital Ratio fell to 1.28 a new company low.
Within Major Pharmaceutical Preparations industry 351 other companies have achieved higher Working Capital Ratio than Fibrogen Inc in third quarter 2024. While Working Capital Ratio total ranking has improved so far during the Q3 2024 to 2450, from total ranking in the second quarter 2024 at 2624.
Explain Working Capital Ratio
How much Current Assetss FGEN´s has?
What are FGEN´s Current Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| FGEN Working Capital Ratio |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
(Dec 31 2023)
Q4 |
(Sep 30 2023)
Q3 |
| Y / Y Current Liabilities Change |
-9.02 % |
-23.44 % |
-22.77 % |
-20.43 % |
-16.9 % |
| Y / Y Current Assets Change |
-32.84 % |
-49.08 % |
-35.39 % |
-32.72 % |
-23.22 % |
| Working Capital Ratio MRQ |
1.28 |
1.41 |
1.41 |
1.52 |
1.74 |
| FGEN's Total
Ranking |
# 2450 |
# 2624 |
# 2194 |
# 2490 |
# 2666 |
| Seq. Current Liabilities Change |
28.23 % |
-24.47 % |
-9.62 % |
3.94 % |
7.91 % |
| Seq. Current Assets Change |
16.74 % |
-24.7 % |
-16.1 % |
-8.94 % |
-11.49 % |
| Working Capital Ratio third quarter 2024 Company Ranking |
| Within: |
No. |
| Major Pharmaceutical Preparations Industry |
# 352 |
| Healthcare Sector |
# 708 |
| Overall Market |
# 2450 |
| Working Capital Ratio Statistics |
| High |
Average |
Low |
| 11.14 |
4.73 |
1.28 |
| (Mar 31 2020) |
|
(Sep 30 2024) |
Cumulative Fibrogen Inc 's Working Capital Ratio
FGEN's Working Capital Ratio for the trailling 12 Months
FGEN Working Capital Ratio |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
(Dec 31 2023)
12 Months |
(Sep 30 2023)
12 Months |
| Y / Y Current Liabilities TTM Growth |
-9.02 % |
-23.44 % |
-22.77 % |
-20.43 % |
-16.9 % |
| Y / Y Current Assets TTM Growth |
-32.84 % |
-49.08 % |
-35.39 % |
-32.72 % |
-23.22 % |
| Working Capital Ratio TTM |
1.41 |
1.53 |
1.69 |
1.76 |
1.82 |
| Total
Ranking TTM |
# 2798
| # 3583
| # 2797
| # 3595
| # 4083
|
| Seq. Current Liabilities TTM Growth |
28.23 % |
-24.47 % |
-9.62 % |
3.94 % |
7.91 % |
| Seq. Current Assets TTM Growth |
16.74 % |
-24.7 % |
-16.1 % |
-8.94 % |
-11.49 % |
On the trailing twelve months basis In spite of the year on year decrease in FGEN's Current Liabilities to $190.53 millions, cumulative Working Capital Ratio to 1.41 below the FGEN average Working Capital Ratio. Working Capital Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 378 other companies have achieved higher Working Capital Ratio than Fibrogen Inc . While Working Capital Ratio overall ranking has improved so far to 2798, from total ranking during the twelve months ending second quarter 2024 at 3583.
Explain Working Capital Ratio
How much Current Assetss FGEN´s has?
What are FGEN´s Current Liabilities?
| TTM Working Capital Ratio Company Ranking |
| Within: |
No. |
| Within the Major Pharmaceutical Preparations Industry |
# 379 |
| Healthcare Sector |
# 790 |
| Within the Market |
# 2798 |
| trailing twelve months Working Capital Ratio Statistics |
| High |
Average |
Low |
| 9.16 |
5 |
1.41 |
| (Jun 30 2018) |
|
(Sep 30 2024) |
|
Date modified: 2024-11-13T14:43:04+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
